To compare the incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in patients with metastatic melanoma treated with antiprogrammed cell death-1, BRAF inhibitor monotherapy or dabrafenib and trametinib combination therapy (CombiDT)
Latest Information Update: 01 Oct 2019
At a glance
- Drugs Dabrafenib (Primary) ; Dabrafenib/trametinib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Oct 2019 New trial record